• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Amicus acquires Scioderm for $847M

Amicus acquires Scioderm for $847M

August 31, 2015
CenterWatch Staff

Cranbury, N.J.-based Amicus Therapeutics has inked a deal to acquire Durham, N.C.-based Scioderm, a privately held biopharmaceutical company, for about $847 million.

The deal places Scioderm’s lead product candidate Zorblisa, a topical cream for the treatment of epidermolysis bullosa (EB), into Amicus’ rare and orphan disease pipeline.

In a prepared statement, Amicus CEO John F. Crowley, who serves on the Scioderm board of directors, said Zorblisa will bring relief to patients living with EB.

“EB is a disorder that is utterly devastating and painful as it causes extremely fragile skin that blisters and tears from minor friction or trauma. In many children, it leads to severe complications and a very early death,” said Crowley. “We believe we are well-positioned to rapidly complete the clinical development of Zorblisa and to make Zorblisa commercially available for all EB patients as quickly as possible.”

Zorblisa is now in phase III trials. In 2013, it received a Breakthrough Therapy designation from the FDA after early trials showed its ability to help heal wounds across the spectrum of EB subtypes.

Amicus estimated that Zorblisa will generate $1 billion in annual revenues. Existing treatments for EB have a monthly cost of between $10,000 and $15,000. The company said most treatments are palliative in nature and consist primarily of “bandaging, treating the open wounds to prevent infection and trying to manage patients’ pain.” According to a company estimate, there are between 30,000 and 40,000 people “in major markets” who have been diagnosed with EB.

The acquisition of Scioderm fits into Amicus’ plan of bringing more first-in-class, rare-disease drugs into the company. Crowley has said he first proposed the deal to Scioderm earlier this year.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing